Mechanisms linking obesity with cardiovascular disease

Nature

Volumn 444, Issue 7121, 2006, Pages 875-880

  Van Gaal, Luc F ^a   Mertens, Ilse L ^a   De Block, Christophe E ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; FATTY ACID; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR DISEASE; DIABETES; HEALTH RISK; HOMEOSTASIS; MORTALITY RISK; OBESITY;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENERGY EXPENDITURE; FIBRINOLYSIS; HEART VENTRICLE REMODELING; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOKING; VASCULAR SMOOTH MUSCLE;

EID: 33845914986     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05487     Document Type: Review

References (81)

1. James, P .T., Rigby, N. & Leach, R. International Obesity Task Force. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur. J. Cardiovasc. Prev. Rehabil. 11, 3-8 (2004).
2. Adams, K. F. et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N. Engl. J. Med. 355, 763-778 (2006).
3. Lakka, T. A., Lakka, H. M., Salonen, R., Kaplan, G. A. & Salonen, J. T. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis 154, 497-504 (2001).
4. Kenchaiah, S. et al. Obesity and the risk of heart failure. N. Engl. J. Med. 347, 305-313 (2002).
5. Hu, F. B. et al. Adiposity as compared with physical activity in predicting mortality among women. N. Engl. J. Med. 351, 2694-2703 (2004).
6. Berenson, G. S. et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 338, 1650-1656 (1998).
7. Olshansky, S. J. et al. A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 352,1138-1145 (2005).
8. Eckel, R. H., Kahn, R., Robertson, R. M. & Rizza, R. A. Preventing cardiovascular disease and diabetes. A call to action from the American Diabetes Association and the American Heart Association. Circulation 113, 2943-2946 (2006).
9. Lau, D. C. W., Dhillon, B., Yan, H., Szmitko, P. E. & Verma, S. Adipokines: molecular links between obesity and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 288, H2031-H2041 (2005).
10. Poirier, P. et al. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113, 898-918 (2006).
11. Peeters, A. et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann. Intern. Med. 138, 24-32 (2003).
12. Stevens, J., Cai, J., Evenson, K. R. & Thomas, R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am. J. Epidemiol. 156, 832-841 (2002).
13. Pontiroli, A. E. et al. Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. Eur. J. Endocrinol. 150, 195-200 (2004).
14. Blann, A. D., Steele, C. & McCollum, C. N. The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb. Res. 85, 433-438 (1997).
15. Iwashima, Y. et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension 45, 1094-1100 (2005).
16. Matsuzawa, Y. The metabolic syndrome and adipocytokines. FEBS Lett. 580, 2917-2921 (2006).
17. Liu, R., Mizuta, M. & Matsukura, S. The expression and functional role of nicotinic acetylcholine receptors in rat adipocytes. J. Pharmacol. Exp. Ther. 310, 52-58 (2004).
18. Facchini, F. S., Hollenbeck, C. B., Jeppesen, J., Chen, Y. D. & Reaven, G. M. Insulin resistance and cigarette smoking. Lancet 339, 1128-1130 (1992).
19. van der Vaart, H., Postma, D. S., Timens, W. & Ten Hacken, N. H. T. Acute effects of cigarette smoking on inflammation and oxidative stress: a review. Thorax 59, 713-721 (2004).
20. Howard, B. V., Ruotolo, G. & Robbins, D. C. Obesity and dyslipidemia. Endocrinol. Metab. Clin. N. Am. 32, 855-867 (2003).
21. Yusuf, S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937-952 (2004).
22. Gaudet, D. et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 97, 871-877 (1998).
23. Nicholls, S. J. et al. Effects of obesity on lipid-lowering, anti-inflammatory and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL study). Am. J. Cardiol. 97, 1553-1557 (2006).
24. Kwiterovich, P.O. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am. J. Cardiol. 90, 30i-47i (2002).
25. Taskinen, M.R. Lipoprotein lipase in diabetes. Diabetes Metab. Rev. 3, 551-570 (1987).
26. Howard, B. V. et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. 20, 830-835 (2000).
27. Chan, D. C., Watts, G. F., Redgrave, T. G., Mori, T. A. Barrett, P. H. R. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 51, 1041-1046 (2002).
28. Frenais, R. et al. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus. J. Clin. Endocrinol. Metab. 86, 1962-1967 (2001).
29. Mertens, I. & Van Gaal, L. F. New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP-ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome. J. Thromb. Haemost. 4, 1164-1166 (2006).
30. Blair, S. N. & Church, T. S. The fitness, obesity, and health equation: is physical activity the common denominator? J. Am. Med. Assoc. 292, 1232-1234 (2004).
31. Li, T. Y. et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation 113, 499-506 (2006).
32. Manson, J. E. et al. Body weight and mortality among women. N. Engl. J. Med. 333, 677-685 (1995).
33. Sandvik, L. et al. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N. Engl. J. Med. 328, 533-537 (1993).
34. Nigro, J., Osman, N., Dart, A. M. & Little, P. J. Insulin resistance and atherosclerosis. Endocr. Rev. 27, 242-259 (2006).
35. Ferrannini, E. & Iozzo, P. Is insulin resistance atherogenic? A review of the evidence. Atheroscler. Suppl. 7, 5-10 (2006).
36. Smith, S. R. & Wilson, P. W. Free fatty acids and atherosclerosis - guilty or innocent? J. Clin. Endocrinol. Metab.91, 2506-2508 (2006).
37. Pilz, S. et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J. Clin. Endocrinol. Metab. 91, 2542-2547 (2006).
38. Graham, T. E. et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354, 2552-2563 (2006).
39. Abel, E. D. et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409, 729-733 (2001).
40. Summers, S. A. et al. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45, 42-72 (2006).
41. Rexrode, K. M. et al. Abdominal adiposity and coronary heart disease in women. J. Am. Med. Assoc. 280, 1843-1848 (1998).
42. Després, J. P., Lemieux, I. & Prud'homme, D. Treatment of obesity: need to focus on high risk abdominally obese patients. Br. Med. J. 322, 716-720 (2001).
43. Kuk, J. L. et al. Visceral fat is an independent predictor of all-cause mortality in men. Obesity 14, 336-342 (2006).
44. Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808 (2003).
45. Cancello, R. & Clement, K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 113, 1141-1147 (2006).
46. Bornstein, S. R. et al. Immunohistochemical and ultrastructural localization of leptin and leptin receptor in human white adipose tissue and differentiating human adipose cells in primary culture. Diabetes 49, 532-538 (2000).
47. Björntorp, P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10, 493-496 (1990).
48. Yki-Jarvinen, H. & Westerbacka, J. The fatty liver and insulin resistance. Curr. Mol. Med. 5, 287-295 (2005).
49. Yusuf, S. et al. INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366, 1640-1649 (2005).
50. Montani, J.-P. et al. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int. J. Obesity 28, S58-S65 (2004).
51. Zhou, Y. T. et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl Acad. Sci. USA 97, 1784-1789 (2000).
52. McGavock, J. M., Victor, R. G., Unger, R. H. & Szczepaniak, L. S. American College of Physicians and the American Physiological Society. Adiposity of the heart, revisited. Ann. Intern. Med. 144, 517-524 (2006).
53. Szczepaniak, L. S. et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn. Reson. Med. 49, 417-423 (2003).
54. Verlohren, S. et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 44, 271-276 (2004).
55. Arita, Y. et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105, 2893-2898 (2002).
56. Konstantinides, S., Schafer, K., Koschnick, S. & Loskutoff, D. J. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J. Clin. Invest. 108, 1533-1540 (2001).
57. Singhal, A. et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 106, 1919-1924 (2002).
58. Mertens, I., Considine, R. V., Van der Planken, M. & Van Gaal, L. F. Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? Eur. J. Endocrinol. 155, 477-484 (2006).
59. Kumada, M. et al. Adiponectin specifically increases tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109, 2046-2049 (2004).
60. Kobayashi, H. et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res. 94, e27-e31 (2004).
61. Ouchi, N. et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42, 231-232 (2003).
62. Fukuhara, A. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307, 426-430 (2005).
63. Haider, D. G. et al. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49, 1909-1914 (2006).
64. Mertens, I. & Van Gaal, L. F. Obesity, haemostasis and the fibrinolytic system. Obes. Rev. 3, 85-101 (2002).
65. Bastelica, D. et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler. Thromb. Vasc. Biol. 22, 173-178 (2002).
66. Alessi, M. C. et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler. Thromb. Vasc. Biol. 23, 1262-1268 (2003).
67. Alessi, M. C. & Juhan-Vague, I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler. Thromb. Vasc. Biol. 26, 200-207 (2006).
68. Esmon, C. T. The interactions between inflammation and coagulation. Br. J. Haematol. 131, 417-430 (2005).
69. Hanley, A. J. et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 53, 1773-1781 (2004).
70. Devaraj, S., Xu, D. Y. & Jialal, I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107, 398-404 (2003).
71. Ceriello, A. & Motz, E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol. 24, 816-823 (2004).
72. Holvoet, P. et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging and body composition cohort. Diabetes 53, 1068-1073 (2004).
73. Maddux, B. A. et al. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of alpha-lipoic acid. Diabetes 50, 404-410 (2001).
74. Esposito, K. et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106, 2067-2072 (2002).
75. Tripathy, D. et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52, 2882-2887 (2003).
76. Sattar, N. et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 53, 2855-2860 (2004).
77. Libby, P., Ridker, P. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135-1143 (2002).
78. Berg, A. H., Scherer, P. E. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96, 939-949 (2005).
79. Berg, A. H., Lin, Y., Lisanti, M. P. & Scherer, P. E. Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am. J. Physiol. Endocrinol. Metab. 287, E1178-E1188 (2004).
80. Rutter, M. K. et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107, 448-454 (2003).
81. Young, M. E. et al. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 105, 1861-1870 (2002).